05Apr/13

Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and … – MarketWatch (press release)

Emergent BioSolutions to Expand Front Line CLL Clinical Trial of TRU-016 and
MarketWatch (press release)
“Emergent is pleased with the progress of our Phase 1b study of TRU-016 in combination with rituximab in front line patients with CLL. The strong enrollment and the encouraging early data from this open label study are expected to facilitate an

and more »

05Apr/13

Brisk walking as good as running for heart – Times of India


Times of India

Brisk walking as good as running for heart
Times of India
They found that the same energy used for moderate intensity walking and vigorous intensity running resulted in similar reductions in risk for high blood pressure, high cholesterol, diabetes, and possibly coronary heart disease over the study’s six years.
Brisk walking as good as running for heart: StudyDaily News & Analysis

all 42 news articles »